ImmunoGen shares pushed higher to start out the week when the FDA provided an update for the firm’s treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Truist Securities initiated CorMedix with a Buy rating and a $20 price target. The stock closed below $5 a share on Friday.
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday. 
Companies winning approval from the FDA or beating a trial are expected in some cases. If investors already have priced this news into the stock, when it actually comes around they tend to sell the...
The FDA has approved Innoviva's treatment of asthma and for patients with chronic obstructive pulmonary disease, the company announced, giving shares a boost early Thursday.
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
A key update from the FDA on its treatment for relapsed/refractory multiple myeloma boosted Precision BioSciences shares early on Wednesday.
Corbus Pharmaceuticals has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
Plus Therapeutics shares rallied on Tuesday after an FDA update on its treatment of patients with recurrent glioblastoma.
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
BioMarin Pharmaceutical stock was crushed on Wednesday after an FDA response regarding its valoctocogene roxaparvovec gene therapy for severe hemophilia A.